|
Mar 15
|
BioSyent Full Year 2024 Earnings: Misses Expectations
|
|
Mar 13
|
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2024
|
|
Jul 24
|
FAX Capital Files Early Warning Report Regarding Disposition of Common Shares of BioSyent Inc.
|
|
Feb 6
|
BioSyent Declares First Quarter 2024 Dividend
|
|
Aug 8
|
BioSyent Launches Inofolic® for Women with Polycystic Ovary Syndrome (PCOS)
|
|
Jul 6
|
BioSyent Pharma to Introduce Gelclair® at AHNS 11th International Conference on Head and Neck Cancer
|